{
    "medicine_id": "4e1473fba748a253c8111804d843881cc8bc2d29",
    "platform_id": "13278",
    "metadata": {
        "name": "Nevirapine Milpharm 400 mg Prolonged release tablets",
        "composition": "Each prolonged release tablet contains 400 mg nevirapine",
        "clinical_particulars": {
            "therapeutic_indications": "Nevirapine is indicated in combination with other anti retroviral medicinal products for the treatment of HIV 1 infected adults adolescents and children three years and above and able to swallow tablets see section 4 2 Prolonged release tablets are not suitable for the 14 day lead in phase for patients starting nevirapine Other nevirapine formulations such as immediate release tablets or oral suspension should be used see Section 4 2 Most of the experience with nevirapine is in combination with nucleoside reverse transcriptase inhibitors NRTIs The choice of a subsequent therapy after nevirapine should be based on clinical experience and resistance testing see section 5 1",
            "contraindications": {
                "disease": "Hypersensitivity to the active substance or to any of the excipients listed in section 6 1 Readministration to patients who have required permanent discontinuation for severe rash rash accompanied by constitutional symptoms hypersensitivity reactions or clinical hepatitis due to nevirapine Patients with severe hepatic impairment Child Pugh C or pre treatment ASAT or ALAT 5 ULN until baseline ASAT ALAT are stabilised 5 ULN Readministration to patients who previously had ASAT or ALAT 5 ULN during nevirapine therapy and had recurrence of liver function abnormalities upon readministration of nevirapine see section 4 4 Coadministration with herbal preparations containing St John s wort Hypericum perforatum due to the risk of decreased plasma concentrations and reduced clinical effects of nevirapine see section 4 5",
                "pregnancy": "Applicable",
                "machine_ops": "Applicable",
                "excipients": "Lactose monohydrate;Hypromellose (4000 mPas, controlled release grade);Iron oxide yellow (E172);Silica colloidal anhydrous;Sodium stearyl fumarate",
                "incompatibilities": "Not applicable."
            }
        },
        "revision_date": "2022-03-11"
    }
}